Home Cell Therapy Sweet Spot: CRISPR Therapeutics, ViaCyte Dose First Patient with Cell Therapy for...

ViaCyte_engineering (1) — CRISPR Therapeutics and ViaCyte have dosed the first patient in a Phase I trial designed to evaluate their cell therapy VCTX210 for safety, tolerability, and immune evasion. VCTX210 is designed to engineer ViaCyte’s CyT49 pluripotent human stem cell line via CRISPR Therapeutics’ gene editing technology, in order to avoid destruction by the patient’s immune system, potentially eliminating the need for immunosuppressants. [ViaCyte]

Sweet Spot: CRISPR Therapeutics, ViaCyte Dose First Patient with Cell Therapy for Type 1 Diabetes

VCTX210 uses gene editing to engineer ViaCyte’s CyT49 pluripotent human stem cell line, to avoid destruction by the immune system

By Alex Philippidis

March 14, 2022

CRISPR Therapeutics and ViaCyte have dosed the first patient in a Phase I trial designed to evaluate their cell therapy VCTX210 for safety, tolerability, and immune evasion. VCTX210 is designed to engineer ViaCyte’s CyT49 pluripotent human stem cell line via CRISPR Therapeutics’ gene editing technology, in order to avoid destruction by the patient’s immune system, potentially eliminating the need for immunosuppressants. [ViaCyte]

VCTX210 (formerly PEC-QT™) is an investigational allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for treatment of type 1 diabetes. VCTX210 is designed to engineer ViaCyte’s CyT49 pluripotent human stem cell line via CRISPR Therapeutics’ gene editing technology to avoid destruction by the patient’s immune system, potentially eliminating the need for chronic immunosuppressants. If VCTX210 is found to be safe and immune evasive, the trial may expand to assess therapeutic dosing . . .